CSIMarket
 
Soligenix inc   (SNGX)
Other Ticker:  
 

Soligenix inc

Business Description


Soligenix Inc. is a pharmaceutical company based in Princeton, New Jersey, that develops and commercializes innovative therapeutics for rare diseases. The company focuses on two main areas: inflammation and oncology.

In the field of inflammation, Soligenix is primarily involved in the development of a drug called SGX301. SGX301 is a synthetic hypericin, a photosensitizer, used in conjunction with safe, visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin*s lymphoma. The drug is administered topically and activates an immune response against the cancerous cells. SGX301 has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), highlighting its potential benefits for an underserved patient population.

Soligenix is also active in the field of gastrointestinal disorders. The company has developed a product called SGX942, a novel synthetic innate defense regulator (IDR) peptide, for the treatment of oral mucositis. Oral mucositis is a common and debilitating side effect of certain cancer treatments, including radiation and chemotherapy. SGX942 works by modulating the immune response, reducing inflammation, and promoting wound healing in the oral cavity. The drug has demonstrated positive results in clinical trials and has also received both Fast Track and Orphan Drug designations from the FDA.

In addition to these primary focus areas, Soligenix is engaged in the development of a ricin toxin vaccine called RiVax. Ricin is a potent toxin found in castor beans and can be used as a bioweapon. RiVax is being developed as a medical countermeasure against ricin exposure, with the goal of protecting military personnel and civilians in case of a potential bioterrorism event. Soligenix has received both financial support and collaboration from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of RiVax.

Furthermore, Soligenix has a robust medical countermeasures program, which includes the development of vaccines, therapeutics, and diagnostics for a range of infectious diseases and emerging pathogens. This program is supported by grants and contracts from various governmental agencies, such as the Department of Defense.

In terms of partnerships and collaborations, Soligenix has worked with both industry and academic partners to advance its product pipeline. For instance, the company has collaborated with the University of Pennsylvania and the University of Pittsburgh for the development of its SGX942 product. Soligenix has also established partnerships with organizations like Emergent BioSolutions and CRO Services to support its clinical trials and manufacturing processes.

In summary, Soligenix Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for rare diseases. With a primary focus on inflammation and oncology, the company?s pipeline includes potential treatments for cutaneous T-cell lymphoma, oral mucositis, and ricin toxin exposure. Supported by grants and partnerships, Soligenix continues to advance its medical countermeasures program to address various infectious diseases and emerging pathogens.



View Company Supplier View Company Competition View Company Customers


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com